BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

Dupixent bounces back in treating hives with FDA approval
The U.S. FDA issued a complete response letter in October 2023 for Dupixent (dupilumab) in treating chronic hives but has now approved the monoclonal antibody for the...

More in BioWorld

BioWorld MedTech

Medtronic continues to close gap in diabetes tech
Medtronic plc’s diabetes unit posted another win with the U.S. FDA approval of the Simplera continuous glucose monitoring sensor for use with the Minimed 780G pump system,...

More in BioWorld MedTech

BioWorld Science

WHO member states outline pandemic plan
After more than three years of discussion, the World Health Organization’s Intergovernmental Negotiating Body (INB) has agreed on a proposal to prevent, prepare and respond...

More in BioWorld Science

BioWorld Asia

Hightide’s HTD-1801 meets phase III endpoints in type 2 diabetes
Hightide Therapeutics Inc.’s berberine ursodeoxycholate (HTD-1801) met primary and secondary endpoints in the Symphony 1 and Symphony 2 phase III trials in type 2 diabetes...

More in BioWorld Asia

BioWorld Insider Podcast

As biopharma investments stumble, med tech surges: This year’s med-tech investments include $2.76B via 56 transactions in January alone. BioWorld MedTech Editor Annette Boyle discusses why the sector is performing well year to date.